| Patient | Yul Brynner |
|---|---|
| Date of birth | 1920-07-11 |
| Identifiers | MRN HR-ML020-SYN-TD; SSN (made up) 000-20-4572 |
| Document date | 2026-11-01 |
| Author | Simon Achterberg, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT. Concerns: His voice has become weak and breathy, and he cannot sing or project on stage; He wants to get back to performing and to keep working for as long as he can; He wants people to know what smoking did to him. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks | Every 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panel | Intravenous route | 1983-09-22 | active | S |
| Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases | Every 12 weeks, after calcium and creatinine, with a dental examination done first | Intravenous route | 1983-10-13 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid | One tablet by mouth daily | Oral route | 1983-10-13 | active | S |
| Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds) | Apply a thin layer twice daily for up to two weeks | Topical route | 1983-10-20 | active | S |
| Cetirizine 10 mg oral tablet, one tablet daily as needed for itching | One tablet by mouth daily as needed for itching | Oral route | 1983-10-20 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Flexible laryngoscopy by the ENT surgeon: left vocal fold immobile in the paramedian position with incomplete glottic closure; no laryngeal mass or mucosal lesion | 1983-09-01 to 1983-09-01 | completed | S |
| CT of the chest, abdomen, and pelvis with contrast: 5.2 cm left upper lobe mass invading the mediastinal fat of the aortopulmonary window and abutting the aortic arch and left pulmonary artery; enlarged aortopulmonary window (2.4 cm) and subcarinal (1.8 cm) lymph nodes; a small lytic lesion in the T10 vertebral body; no adrenal or liver lesion | 1983-09-01 to 1983-09-01 | completed | S |
| FDG PET-CT: avid left upper lobe mass (SUVmax 14) with mediastinal invasion; avid aortopulmonary window and subcarinal nodes (N2); no contralateral or supraclavicular nodes; avid lytic lesions at T10, the right ilium, and the left sixth rib, without fracture (M1c) | 1983-09-04 to 1983-09-04 | completed | S |
| MRI of the brain with contrast: no metastases | 1983-09-04 to 1983-09-04 | completed | S |
| Endobronchial ultrasound-guided needle aspiration of subcarinal (station 7) and left lower paratracheal (4L) nodes: adenocarcinoma, TTF-1 and napsin A positive; PD-L1 (22C3) tumor proportion score 70 percent; tissue sent for comprehensive next-generation sequencing (reported 12 days later: KRAS G12V and TP53 mutations; no EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK, HER2, or NRG1 alteration), with concordant plasma cell-free DNA testing | 1983-09-09 to 1983-09-09 | completed | S |
| Outpatient palliative care visit: symptom assessment, coping, goals of care, and a plan for breathlessness and cough | 1983-09-29 to 1983-09-29 | completed | S |
| Office injection medialization of the left vocal fold under laryngoscopic guidance by the ENT surgeon, to improve glottic closure and voice | 1983-10-06 to 1983-10-06 | completed | S |
| Advance care planning conversation, about 30 minutes | 1983-10-27 to 1983-10-27 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1982-10-21 | Influenza vaccine, 1982-1983 season | completed | S |
| 1977-03-17 | Tdap vaccine | completed | S |
| 1983-10-27 | Influenza vaccine, 1983-1984 season | completed | S |
| 1983-10-27 | Pneumococcal conjugate vaccine PCV20, single dose | completed | S |
| 1983-10-27 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1971 | Heavy cigarette smoking for decades, quit twelve years before the index visit | D (CLM-0004) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| His voice has become weak and breathy, and he cannot sing or project on stage | active | S |
| He wants to get back to performing and to keep working for as long as he can | active | S |
| He wants people to know what smoking did to him | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13.5 on 1983-10-13; Leukocytes [#/volume] in Blood by Automated count 7.2 on 1983-10-13; Platelets [#/volume] in Blood by Automated count 270 on 1983-10-13; Sodium [Moles/volume] in Serum or Plasma 138 on 1983-09-01; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1983-09-01; Creatinine [Mass/volume] in Serum or Plasma 0.9 on 1983-10-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M 92 on 1983-10-13; Calcium [Mass/volume] in Serum or Plasma 9.4 on 1983-10-13; Albumin [Mass/volume] in Serum or Plasma 4 on 1983-09-01; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 on 1983-10-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 25 on 1983-10-20; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 101 on 1983-09-22; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 1983-10-20; Glucose [Mass/volume] in Serum or Plasma 104 on 1983-10-13; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 1983-10-13; Total score [Edmonton Symptom Assessment System] 12 on 1983-10-13; Thyrotropin [Units/volume] in Serum or Plasma 2.6 on 1983-10-20; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.1 on 1983-10-20; Cortisol [Mass/volume] in Serum or Plasma 14.2 on 1983-09-22; Eosinophils [#/volume] in Blood by Automated count 0.62 on 1983-10-20; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1983-10-27; Total score [AUDIT-C] 2 on 1983-10-27 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes | active | confirmed | C34.12 | S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983. |
| Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer. |
| Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window | active | confirmed | J38.01 | S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor. |
| Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis | active | confirmed | R91.8 | S — Synthetic presenting imaging finding, recorded before the tissue diagnosis. |
| Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since | active | confirmed | Z87.891 | S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts. |
| Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement) | active | confirmed | L27.0 | S — Synthetic common immune-related adverse event on checkpoint inhibitor therapy. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1983-09-01 | Hemoglobin [Mass/volume] in Blood | 13.8 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1983-09-01 | Leukocytes [#/volume] in Blood by Automated count | 7.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1983-09-01 | Platelets [#/volume] in Blood by Automated count | 290 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1983-09-01 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1983-09-01 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1983-09-01 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1983-09-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M | 92 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1983-09-01 | Calcium [Mass/volume] in Serum or Plasma | 9.6 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1983-09-01 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 1983-09-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-55 U/L | Normal | S |
| 1983-09-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 8-48 U/L | Normal | S |
| 1983-09-01 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 98 | U/L | 40-129 U/L | Normal | S |
| 1983-09-01 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1983-09-01 | Glucose [Mass/volume] in Serum or Plasma | 96 | mg/dL | 70-99 mg/dL | Normal | S |
| 1983-09-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1983-09-15 | Total score [Edmonton Symptom Assessment System] | 18 | {score} | S | ||
| 1983-09-22 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1983-09-22 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1983-09-22 | Cortisol [Mass/volume] in Serum or Plasma | 14.2 | ug/dL | Morning (8 a.m.) reference interval | Normal | S |
| 1983-09-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-55 U/L | Normal | S |
| 1983-09-22 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 23 | U/L | 8-48 U/L | Normal | S |
| 1983-09-22 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 101 | U/L | 40-129 U/L | Normal | S |
| 1983-09-22 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1983-09-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1983-09-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M | 92 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1983-09-22 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1983-09-22 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1983-09-22 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1983-09-22 | Leukocytes [#/volume] in Blood by Automated count | 7.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1983-09-22 | Platelets [#/volume] in Blood by Automated count | 284 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1983-10-13 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1983-10-13 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1983-10-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-55 U/L | Normal | S |
| 1983-10-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-48 U/L | Normal | S |
| 1983-10-13 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1983-10-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1983-10-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M | 92 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1983-10-13 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 1983-10-13 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1983-10-13 | Hemoglobin [Mass/volume] in Blood | 13.5 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1983-10-13 | Leukocytes [#/volume] in Blood by Automated count | 7.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1983-10-13 | Platelets [#/volume] in Blood by Automated count | 270 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1983-10-13 | Total score [Edmonton Symptom Assessment System] | 12 | {score} | S | ||
| 1983-10-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1983-10-20 | Thyrotropin [Units/volume] in Serum or Plasma | 2.6 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1983-10-20 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 1983-10-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-55 U/L | Normal | S |
| 1983-10-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 | U/L | 8-48 U/L | Normal | S |
| 1983-10-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1983-10-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 1983-10-20 | Eosinophils [#/volume] in Blood by Automated count | 0.62 | 10*3/uL | 0-0.5 10*3/uL | High | S |
| 1983-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1983-10-27 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1983-09-01 | Body height | 178 | cm | S |
| 1983-09-01 | Body weight | 72.4 | kg | S |
| 1983-09-01 | Body mass index (BMI) [Ratio] | 22.9 | kg/m2 | S |
| 1983-09-01 | Systolic blood pressure | 132 | mm[Hg] | S |
| 1983-09-01 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1983-09-01 | Heart rate | 82 | /min | S |
| 1983-09-01 | Respiratory rate | 16 | /min | S |
| 1983-09-01 | Body temperature | 36.8 | Cel | S |
| 1983-09-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1983-09-15 | Body height | 178 | cm | S |
| 1983-09-15 | Body weight | 72 | kg | S |
| 1983-09-15 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 1983-09-15 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1983-09-15 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1983-09-15 | Heart rate | 80 | /min | S |
| 1983-09-15 | Respiratory rate | 16 | /min | S |
| 1983-09-15 | Body temperature | 36.7 | Cel | S |
| 1983-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1983-09-22 | Body height | 178 | cm | S |
| 1983-09-22 | Body weight | 71.8 | kg | S |
| 1983-09-22 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 1983-09-22 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1983-09-22 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1983-09-22 | Heart rate | 78 | /min | S |
| 1983-09-22 | Respiratory rate | 16 | /min | S |
| 1983-09-22 | Body temperature | 36.6 | Cel | S |
| 1983-09-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1983-10-13 | Body height | 178 | cm | S |
| 1983-10-13 | Body weight | 72.2 | kg | S |
| 1983-10-13 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 1983-10-13 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1983-10-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1983-10-13 | Heart rate | 76 | /min | S |
| 1983-10-13 | Respiratory rate | 16 | /min | S |
| 1983-10-13 | Body temperature | 36.7 | Cel | S |
| 1983-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1983-10-20 | Body height | 178 | cm | S |
| 1983-10-20 | Body weight | 72 | kg | S |
| 1983-10-20 | Body mass index (BMI) [Ratio] | 22.7 | kg/m2 | S |
| 1983-10-20 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1983-10-20 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1983-10-20 | Heart rate | 78 | /min | S |
| 1983-10-20 | Respiratory rate | 16 | /min | S |
| 1983-10-20 | Body temperature | 36.7 | Cel | S |
| 1983-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1983-10-27 | Body height | 178 | cm | S |
| 1983-10-27 | Body weight | 72.3 | kg | S |
| 1983-10-27 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 1983-10-27 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1983-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1983-10-27 | Heart rate | 74 | /min | S |
| 1983-10-27 | Respiratory rate | 16 | /min | S |
| 1983-10-27 | Body temperature | 36.6 | Cel | S |
| 1983-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1983-09-01 | New patient visit for six weeks of hoarseness, with a left upper lobe mass on same-day CT | finished | S |
| 1983-09-15 | Diagnosis and staging review with thoracic oncology consultation | finished | S |
| 1983-09-22 | Biomarker results and start of first-line pembrolizumab | finished | S |
| 1983-10-13 | Cycle 2 review: immune-related adverse event monitoring, symptoms, and return to work | finished | S |
| 1983-10-20 | Same-day sick visit for an itchy rash on pembrolizumab | finished | S |
| 1983-10-27 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Thoracic oncology consultation for the tissue diagnosis, stage, biomarker plan, first-line therapy, the place of radiation and a bone-modifying agent, and monitoring | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 | S |
| Staging and tissue diagnosis: FDG PET-CT, brain MRI with contrast, and endobronchial ultrasound-guided needle aspiration of the highest-stage node, with enough tissue for PD-L1 and comprehensive next-generation sequencing, and plasma cell-free DNA testing in parallel | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 | S |
| First-line systemic therapy chosen by biomarkers once sequencing excludes an actionable alteration: pembrolizumab 200 mg every 3 weeks for PD-L1 50 percent or more, with response CT every 6 to 12 weeks; switch to 400 mg every 6 weeks to fit the tour once stable | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 | S |
| Immune-related adverse event monitoring: TSH and free T4, liver tests, creatinine, glucose, and blood count before each infusion; morning cortisol at baseline and for symptoms; written list of warning symptoms (diarrhea, cough or breathlessness, rash, yellowing, severe fatigue or headache) with a 24-hour oncology telephone line | completed | GL-ASCO-IRAE-2021, GL-CMID-2026 | S |
| Early integrated palliative care alongside cancer treatment, starting within eight weeks of diagnosis, with symptom (ESAS) and distress screening at each visit and advance care planning | completed | GL-ASCO-PALL-2017, GL-NCCN-DISTRESS-2026, GL-CMID-2026 | S |
| If bone metastases are confirmed: zoledronic acid 4 mg every 12 weeks after a dental examination, with calcium and vitamin D and calcium and creatinine checks before each dose; palliative radiation only if a lesion becomes painful or threatens fracture | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 | S |
| Voice and work: injection medialization of the left vocal fold, voice therapy with a speech-language pathologist, infusions scheduled on his day off, and a graded return to rehearsal and performance as he chooses | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 | S |
| Tobacco: confirm abstinence at each visit; no cessation treatment needed; record the smoking history for his care team | completed | GL-CMID-2026, GL-NCCN-NSCLC-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Tissue diagnosis, full staging, PD-L1, and comprehensive biomarker results before any systemic therapy, within three weeks of presentation | 1983-09-22 | completed | Diagnosis and stage by two weeks; PD-L1 at two weeks and tissue sequencing at three weeks; pembrolizumab started the day the sequencing was reviewed | S |
| First palliative care visit within eight weeks of diagnosis | 1983-10-13 | completed | Seen by the palliative care team two weeks after diagnosis | S |
| A voice strong enough for rehearsal by the second cycle | 1983-10-13 | completed | Louder, less breathy voice one week after injection medialization; light rehearsal resumed with voice therapy | S |
| No grade 2 or higher immune-related adverse event missed: laboratory panel before each infusion and symptom review at each visit | 1983-10-13 | completed | Panels normal before cycles 1 and 2; no symptoms of colitis, pneumonitis, hepatitis, or endocrine dysfunction | S |
| Zoledronic acid started only after a dental examination and normal calcium and kidney function | 1983-10-13 | completed | Dental examination three weeks earlier; calcium 9.4 and eGFR 92; first dose with cycle 2 | S |